SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following news of a significant investment from Nvidia and a collaboration on chip development, sparking optimism about the company's comeback in the semiconductor industry. The community is buzzing about the potential impact on Intel's market position and the broader implications for competition within the chip sector, with some speculating about government influence on the deal.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC Class B Ordinary Shares

Brera Holdings (BREA) is trending due to an oversubscribed $300 million private placement to establish a Solana digital asset treasury, backed by Ark Invest and UAE investors, sparking significant community interest. The company will rebrand as Solmate, focusing on Solana-based digital assets. Community members are actively discussing the potential for dilution and comparing it to similar ventures in the crypto space.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending amid speculation it could become a trillion-dollar company, driven by its exploration of tokenized shares and the projected growth of the tokenized real-world asset market. Community members are actively discussing the potential for new all-time highs and comparing Coinbase's trajectory to that of disruptors like Amazon and Netflix. This comes as the broader crypto market shows signs of strength, influencing positive sentiment around related stocks.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the stock price rallies, driven by optimism around government contracts and potential revenue streams from collaborations. Community members are actively discussing the stock's short interest, potential for a short squeeze, and comparisons to other quantum computing stocks like IONQ.  Some traders express caution, pointing to valuation concerns and the need for a pullback.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as traders discuss the potential impact of the company's possible expansion into AI high-performance computing, fueled by recent CEO comments. The community is analyzing resistance levels and debating whether the stock is currently undervalued compared to its peers, with some anticipating a short squeeze. Bullish investors cite strong revenue growth and margin leverage as reasons for optimism.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

After news of a $1.4 billion AI data center contract in Southeast Asia, $GRRR is trending with community members discussing the potential for a short squeeze and debating the company's valuation relative to its peers in the AI sector. Bullish sentiment is high, with some highlighting upcoming catalysts such as the O.N.E. Amazon event and potential for increased institutional investment, while others are focused on the need for revenue clarity.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney's stock is trending amidst discussions around culture wars and the entertainment giant's content and business decisions. Community perspectives are divided, with some praising the company's potential turnaround and others criticizing perceived political stances. Broader debates encompass streaming strategies, recent news about Jimmy Kimmel, and the impact of these factors on Disney's brand and financial performance.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential implications of Panasonic's recent solid-state battery announcement and its possible connection to QS's technology roadmap, with community members speculating about partnerships with Tesla. Bullish sentiment is fueled by QS's intellectual property and the potential for its technology to revolutionize the EV battery market, contrasting it with competitors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending amid community discussion of a potential short squeeze, driven by its high short interest and recent call options activity. Some investors are pointing to a cup and handle formation as a bullish signal, while others cite potential catalysts like AI partnerships and revenue growth. The stock is also garnering attention within the AI sector, with some comparing its potential to other high-growth tech companies.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders discuss potential pullbacks in the semiconductor sector amid expiring options and debate over market conditions. Community members are weighing the impact of factors like potential rate cuts and earnings reports on semiconductor performance. The conversation includes concerns about market exuberance, the influence of individual stocks like Intel and Nvidia, and the potential for a significant market correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Roivant (ROIV) jumped 9% on Wednesday after the company, along with Priovant Therapeutics, announced positive results from a late-stage trial evaluating Brepocitinib in dermatomyositis.Dermatomyositis is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the U.S. and is characterized by debilitating muscle weakness and skin lesions. No targeted therapies are approved for the condition, and a majority of patients are treated with high-dose oral steroids.Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onset, the company said.On Stocktwits, retail sentiment around ROIV stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_2_05_09_PM_png_94ffd6f84d.webp" alt="ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="619" height="61"><figcaption>ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism that the stock would rally further to $17.<stembedurl>https://stocktwits.com/StockBraker/message/628947861</stembedurl>Another user also cheered the stock’s rally over the past few weeks.<stembedurl>https://stocktwits.com/bbbloo/message/628950392</stembedurl>The company stated that 30mg of Brepocitinib achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo. It added that more than two-thirds of patients receiving the Brepocitinib 30 mg dose experienced at least a moderate response, with a TIS equal to or greater than 40, and nearly half experienced a major response, with a TIS equal to or exceeding 60.Furthermore, 42% of Brepocitinib 30 mg patients were able to discontinue steroids altogether, compared to 23% for the placebo, while 62% achieved a steroid dose of 2.5 mg or less per day. The safety profile observed in the study was consistent with that of previous trials, the company stated.The company plans to file for approval of the drug with the U.S. Food and Drug Administration for the treatment of dermatomyositis in the first half of 2026.ROIV stock is up 31% this year and approximately 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-in-talks-to-renew-jv-with-chinas-saic-report/chDGDTkRd6t">GM In Talks To Renew JV With China’s SAIC: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 

Equity

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 


Dave &amp; Buster's Entertainment (PLAY) was among the top five losers on Stocktwits after multiple price target cuts from Wall Street following its second-quarter sales, which were pressured due to a difficult macro environment and challenges related to the brand.Shares of the company were down nearly 17% before the bell on Tuesday after Dave &amp; Buster’s <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dave-and-busters-stock-plunging-premarket/chwyaxsRdyl">missed quarterly results</a>. UBS cut its price target on Dave &amp; Buster's to $25 from $29 and maintained a ‘Neutral’ rating, according to TheFly.The firm said that <a href="https://stocktwits.com/symbol/PLAY">Dave &amp; Buster's</a> second-quarter results included still pressured sales trends, likely given a difficult macro and brand-specific challenges, while margins and earnings were also depressed.UBS noted that while the company is still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.The retail user message count on the stock jumped 5,200% in the last 24 hours on Stocktwits. Retail sentiment remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:792/102;" src="https://news.stocktwits-cdn.com/PLAY_sentiment_png_f0791affdf.webp" alt="PLAY sentiment.png" width="792" height="102"><figcaption>PLAY sentiment and message volume September 16, 2025, as of 8:10 am ET | Source: Stocktwits</figcaption></figure>Truist Securities cut its price target on Dave &amp; Buster's to $22 from $27 and maintained a ‘Hold’ rating. The firm said that the company's same-store sales decelerated in the back half of the quarter despite much easier year-ago compares as growing macro headwinds offset recent gains from its "back to basics" approach.Brokerage Truist Securities noted that while it sees incremental sales drivers in the second half of 2025, it also sees a risk that consumer pressures mount. Piper Sandler lowered its price target on Dave &amp; Buster's to $26 from $30 and maintained a ‘Neutral’ rating, according to TheFly.A bearish user on Stocktwits noted that there was “no upward catalyst” until the next earnings.<stembedurl>https://stocktwits.com/Bobky2030/message/628801944</stembedurl>Shares of Dave &amp; Buster’s have declined over 17% this year and lost nearly a quarter of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/united-airlines-to-hire-2500-employees-at-newark-airport/chwyLDMRdzb">United Airlines To Hire 2,500 Employees At Newark Airport</a>

The exterior of a Dave & Buster's restaurant is seen on June 10, 2025 in Austin, Texas.

Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot

UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.

In this photo illustration, a smartphone held in a hand shows the logo of The Kroger Co. (NYSE: KR), a U.S. supermarket chain and one of the largest grocery retailers in the country.

Kroger Interim CEO Highlights Shift To Coupons, Private Labels Amid Economic Pressures: ‘Customers Are Feeling Stressed’

However, Ron Sargent also noted that Kroger was adding new households and growing order volumes with existing consumers who already shop with the grocer.

Centene Corporation (CNC) announced on Thursday that the company’s business and financial results through August are consistent with its full-year forecast.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001071739/000107173925000168/cnc-20250911.htm">said</a> in a filing with the U.S. Securities and Exchange Commission that members of its management will discuss the company’s financial results through August at the Deutsche Bank 2025 Healthcare Summit on Thursday. These results, it said, are consistent with the company’s outlook from the July second-quarter earnings call, which stated that it expects full-year adjusted and diluted earnings per share of $1.75.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CNC">CNC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 10% higher at the time of writing.<figure class="image"><img style="aspect-ratio:576/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_11_29_55_AM_png_418f9b242e.webp" alt="CNC's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="576" height="61"><figcaption>CNC's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the rally as the beginning of a recovery back to $50.<stembedurl>https://stocktwits.com/Hornito/message/628314829</stembedurl>Another user expressed optimism that the stock could reach as high as $70.<stembedurl>https://stocktwits.com/Zado148/message/628307192</stembedurl>“...the Medicaid results for July and August were supportive of the HBR (health benefit ratio) improvement trajectory that we're looking for in the back half of the year,” Centene CEO Sarah London said at the event, according to the transcript provided by Fiscal AI. She also added that the medicare segment continues to be on track for the roughly $700 million of improvement the company talked about in July.After the company’s second-quarter earnings fell below Wall Street estimates, London had <a href="https://stocktwits.com/news-articles/markets/equity/centene-reports-unexpected-q2-loss/chobP3PR5w5">said</a> in July that the company has a clear understanding of the trends that impacted its quarterly performance and is working with urgency to restore its earnings trajectory.CNC stock is down by 43% this year and by about 53% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wolfpack-research-reveals-short-position-in-faraday-future/chwNmHARdvm">Wolfpack Research Reveals Short Position In EV Maker Faraday Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Centene Corporation logo seen displayed on a smartphone with the stock market information of Centene Corporation in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Centene Stock Rises After Insurer Reaffirms Full-Year Guidance: Retail Sees Stock Rallying Up To $70

The company said that its July and August results are consistent with the company’s outlook from the July second-quarter earnings call.

Bumble (BMBL) CEO Wolfe Herd and team are reportedly building a new, AI-powered matchmaking app.The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/tech/ai/whitney-wolfe-herd-bumble-ai-398779bb?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">reported</a> on Friday that Bumble has consulted psychologists and relationship counselors to program a matchmaking AI. The company plans to launch a beta version of the app to select users this fall, according to the report, which notes that it will be separate from the existing Bumble app.Shares of the company traded nearly 1% lower by Friday noon. On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/BMBL">BMBL stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The goal behind the AI-powered matchmaking app is to create “the world’s smartest and most emotionally intelligent matchmaker in existence,” the report said, citing Herd. The new app aims to help users build a dating profile based on how they answer questions about past relationships, breakups, and experiences with love and dating, according to the report. It will be built as a large language model, communicating with users in a humanlike way.The team is unsure of how many matches the system will generate, and the monetization strategy is still being determined, the report said. However, users might also have to pay for each match, it said.Once it is ready, the new app will get to know the user over multiple sessions, make a dating profile for them, find them matches, and help book reservations for a date, the report said. BMBL stock is down 23% this year and approximately 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nukkleus-to-form-joint-venture-with-israel-based-mandragola/chtTmaPRdNN">Nukkleus Stock Shot Up A Whopping 37% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. (Photo by Brandon Bell/Getty Images)

Bumble Developing AI-Powered Matchmaking App: Report

 According to The Wall Street Journal, the company plans to launch a beta version of the app to select users this fall, which will be separate from the existing Bumble app. 

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an early-to-mid-stage study as compared to GSK Plc’s (GSK) Shingrix vaccine. &nbsp;Herpes zoster, or shingles, is a viral infection that affects approximately one in three people in their lifetime. The disease is characterized by a painful rash and can lead to serious complications, particularly in older adults.The company evaluated the experimental vaccine in participants aged 50 to 69 years for the first part of the study, and it showed that at one month after the second vaccine dose, Z-1018 <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting">demonstrated</a> immune responses similar to those observed in the arm receiving Shingrix with a favorable tolerability profile.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels. Shares of the company traded 6% higher on Thursday afternoon at the time of writing.<figure class="image"><img style="aspect-ratio:569/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_2_08_19_PM_png_e38a9696ce.webp" alt="DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="569" height="59"><figcaption>DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user suggested holding the stock patiently.<stembedurl>https://stocktwits.com/poorguy/message/626078462</stembedurl>The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year. At the dose formulation and regimen chosen for advancing to the next part of the trial, Z-1018 achieved 100% antibody production compared to Shingrix at 96.9%, the company said.Furthermore, only 12.5% of participants receiving Z-1018 at the dose reported local post-injection reactions, compared to 52.6% for Shingrix, the company said. It also noted that 27.5% participants reported body-wide reactions with the experimental vaccine, compared to 63.2% in Shingrix."These positive data mark an important inflection point for our novel shingles vaccine program as we strive to develop a product with a potential best-in-class profile with the aim to disrupt the multi-billion-dollar shingles vaccine market, which is currently dominated by one product," said CEO Ryan Spencer, referring to Shingrix.DVAX stock is down by 14% this year and by about 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-unveils-new-es8-starting-at-rmb-416800/chsj2ghRdiq">Nio Stock Rocketed 10% Today And Retail Believes It Could Hit The $10-Mark By Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Dynavax company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Autoliv (ALV) CEO Mikael Bratt stated on Friday that the company has already recovered a significant portion of the tariff costs from customers in the second quarter and hopes to recover the remaining later this year.“We remain confident that we can continue to successfully receive compensation from our customers for tariffs, although the industry outlook for tariffs is uncertain. We recovered around 80% of tariff costs in the second quarter, and we expect to recover most of what remains later in the year,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.autoliv.com/press/financial-report-april-june-2025-2377086">said</a> CEO Mikael Bratt.The company stated that U.S. tariffs had an estimated 35 basis points (bps) negative impact on its operating margin in the second quarter (Q2).<a href="https://stocktwits.com/symbol/ALV">Autoliv</a> also increased its full-year guidance for organic sales growth to around 3% from its previous expectation of about 2%, due to tariff compensation. It also reiterated its adjusted operating margin of around 10% to 10.5%.The company’s second-quarter earnings exceeded Wall Street expectations, despite uncertainties related to tariffs. The supplier of automotive safety systems, such as airbags and seatbelts, reported net sales of $2.71 billion, up 4.2% year-over-year and above an analyst estimate of $2.64 billion, according to data from Fiscal AI. &nbsp;While the company’s sales were negatively impacted by reduced light vehicle production in certain regions, such as the Americas and Europe, tariff compensations contributed to growth, the company said.Adjusted and diluted earnings came in at $2.21, compared to $1.87 in the corresponding period of last year, and above an analyst estimate of $2.09.The firm attributed the rise in profits to organic sales growth and successful execution of cost reductions, including measures such as a 5% reduction in total headcount. The company had only 65,100 headcount as of the end of Q2, compared to 68,700 employees at the end of the corresponding quarter in 2024.On Stocktwits, retail sentiment around ALV is currently trending in the ‘bullish’ territory, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_18_at_7_24_44_AM_png_c869f47ba0.webp" alt="ALV's Sentiment Meter and Message Volume as of 7:20 a.m. ET on July 18, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ALV's Sentiment Meter and Message Volume as of 7:20 a.m. ET on July 18, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, none of the 19 analysts covering Autoliv have a ‘Sell’ rating on the stock. While 14 have a ‘strong buy’ rating on the shares of the company, five keep a ‘Hold rating with an average price target of $122.80, marking an upside of over 5%.ALV stock is up 25% this year and approximately 8% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-as-earnings-boost-investor-confidence/ch8kFQZR5qJ">Dow Futures Edge Higher As Strong Earnings Boost Investor Confidence: AXP, NFLX, IBKR, GSK Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Autoliv, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 3, 2025. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

Autoliv Draws Retail Cheer As CEO Says Company Recovered Significant Portion Of Tariff Costs From Customers In Q2

However, the company stated that US tariffs had an estimated 35-basis-point negative impact on its operating margin in the second quarter.

Invesco Capital Management LLC - Invesco BuyBack Achievers ETF

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

PKW
Invesco BuyBack Achievers ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PKW News

PKW Invesco BuyBack Achievers ETF